Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Microsystem Reduces Cost of Developing Ion Channel Drugs

By BiotechDaily International staff writers
Posted on 11 Dec 2013
Image: Schematic diagram of an ion channel. 1 - channel domains (typically four per channel), 2 - outer vestibule, 3 - selectivity filter, 4 - diameter of selectivity filter, 5 - phosphorylation site, 6 - cell membrane (Photo courtesy of Wikimedia Commons).
Image: Schematic diagram of an ion channel. 1 - channel domains (typically four per channel), 2 - outer vestibule, 3 - selectivity filter, 4 - diameter of selectivity filter, 5 - phosphorylation site, 6 - cell membrane (Photo courtesy of Wikimedia Commons).
The use of a microsystem that generates ion channels in a cell-free medium is expected to boost development of drugs that target these channels in the treatment of diseases such as cystic fibrosis, myasthenia gravis, and epilepsy.

The effect of drugs on ion channels is currently studied by electrophysiology, which measures an electric current across ion channel proteins. This, however, is a slow and expensive process that is carried out using ion channels in living cell membranes.

In a paper published in the October 18, 2013, online edition of the journal Analyst, investigators at the University of Southampton (United Kingdom) in collaboration with colleagues at the University of Quebec (Montreal, Canada) described the development of a cell-free expression mixture that allows ion channels to be inserted into stable artificial "cell membranes."

Results of the study showed that single-channel current measurements of the potassium channels KcsA and hERGS5–S6 could be obtained by direct insertion in interdroplet lipid bilayers from microliters of a cell-free expression medium.

"By putting the ion channel into an artificial membrane, we only have one type of channel, no living cells, and a relatively inexpensive method for testing for several of these types of channels at once," said senior author Dr. Maurits de Planque, lecturer in electronics and computer science at the University of Southampton. "Researchers have experimented with cell-free mixtures before, but they found that this method was not economical due to the amount of expensive biochemicals required. Our proposal to develop a new platform, which uses a couple of microliters instead of milliliters, will be a very cost-effective way of doing this, particularly when the produced channel is directly inserted in a membrane for drug testing."

Related Links:

University of Southampton
University of Quebec



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.